Telomerase regulation in hematological cancers: A matter of stemness?
Telomerase regulation in hematological cancers: A matter of stemness?
复制标题
DOI：
10.1016/j.bbadis.2009.01.016
复制
发表时间：
2009-04-01
影响因子：
6.2
通讯作者：
Segal-Bendirdjian, Evelyne
中科院分区：
文献类型：
--
作者：
Deville, Laure;Hillion, Josette;Segal-Bendirdjian, Evelyne
人类端粒酶是一种核核糖-核蛋白酶复合物，催化端粒DNA的合成和延伸。该酶在大多数恶性肿瘤中高度表达和活跃，而在正常体细胞中通常无法或短暂检测到，这表明它在细胞永生和肿瘤发生中起重要作用。由于大多数白血病细胞通常是端粒酶阳性的，并且端粒经常缩短，我们对端粒酶在这些疾病中如何失调的理解可能有助于确定针对端粒/端粒酶复合物的新疗法。尽管如此，考虑到正常的造血干细胞和它们的一些后代确实表达一种功能性的端粒酶，我们很容易将白血病中的这种活性视为一种持续的严重特征，并且理解端粒长度和端粒酶活性如何在各种形式的白血病中被调节是很重要的。(C) 2009 Elsevier B.V.版权所有
Human telomerase is a nuclear ribonucleoprotein enzyme complex that catalyzes the synthesis and extension of telomeric DNA. This enzyme is highly expressed and active in most malignant tumors while it is usually not or transiently detectable in normal somatic cells, suggesting that it plays an important role in cellular immortalization and tumorigenesis. As most leukemic cells are generally telomerase-positive and have often shortened telomeres, our understanding of how telomerase is deregulated in these diseases could help to define novel therapies targeting the telomere/telomerase complex. Nonetheless, considering that normal hematopoietic stem cells and some of their progeny do express a functional telomerase, it is tempting to consider such an activity in leukemias as a sustained sternness feature and important to understand how telomere length and telomerase activity are regulated in the various forms of leukemias. (C) 2009 Elsevier B.V. All rights reserved.